Anja Manuel Purchases 4,000 Shares of Hims & Hers Health, Inc. (NYSE:HIMS) Stock

Hims & Hers Health, Inc. (NYSE:HIMS) Director Anja Manuel bought 4,000 shares of the stock in a transaction dated Tuesday, November 12th. The shares were bought at an average price of $26.94 per share, for a total transaction of $107,760.00. Following the completion of the acquisition, the director now owns 4,000 shares in the company, valued at approximately $107,760. The trade was a ∞ increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Anja Manuel also recently made the following trade(s):

• On Thursday, November 14th, Anja Manuel acquired 1,000 shares of Hims & Hers Health stock. The stock was purchased at an average cost of $24.50 per share, with a total value of $24,500.00.

Hims & Hers Health Stock Down 7.1 %

NYSE HIMS opened at $19.36 on Friday. The firm has a 50-day moving average price of $19.76 and a 200 day moving average price of $18.83. Hims & Hers Health, Inc. has a 52-week low of $7.40 and a 52-week high of $30.44. The stock has a market capitalization of $4.16 billion, a P/E ratio of 44.00 and a beta of 1.06.

Hims & Hers Health (NYSE:HIMS) last announced its quarterly earnings results on Monday, November 4th. The company reported $0.32 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.06 by $0.26. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. The business had revenue of $401.56 million during the quarter, compared to the consensus estimate of $382.20 million. During the same quarter last year, the firm posted ($0.04) EPS. The business’s revenue was up 77.1% compared to the same quarter last year. On average, equities research analysts expect that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research analysts recently weighed in on HIMS shares. Needham & Company LLC began coverage on Hims & Hers Health in a research report on Thursday, August 22nd. They issued a “buy” rating and a $24.00 price objective for the company. Imperial Capital downgraded shares of Hims & Hers Health from an “outperform” rating to an “in-line” rating in a research note on Friday, August 9th. Piper Sandler reaffirmed a “neutral” rating and issued a $21.00 price target (up previously from $18.00) on shares of Hims & Hers Health in a research report on Tuesday, November 5th. Deutsche Bank Aktiengesellschaft raised their price objective on shares of Hims & Hers Health from $23.00 to $27.00 and gave the company a “hold” rating in a report on Wednesday, November 6th. Finally, Bank of America cut Hims & Hers Health from a “buy” rating to an “underperform” rating and decreased their target price for the stock from $32.00 to $18.00 in a research note on Thursday. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating and seven have given a buy rating to the company’s stock. According to MarketBeat.com, Hims & Hers Health currently has a consensus rating of “Hold” and an average price target of $20.71.

Institutional Investors Weigh In On Hims & Hers Health

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Barclays PLC lifted its stake in shares of Hims & Hers Health by 9.7% during the third quarter. Barclays PLC now owns 308,363 shares of the company’s stock valued at $5,680,000 after buying an additional 27,231 shares during the period. Y Intercept Hong Kong Ltd raised its holdings in shares of Hims & Hers Health by 312.6% in the 3rd quarter. Y Intercept Hong Kong Ltd now owns 134,018 shares of the company’s stock worth $2,469,000 after purchasing an additional 101,536 shares during the period. MML Investors Services LLC acquired a new position in Hims & Hers Health during the third quarter valued at approximately $197,000. Main Management ETF Advisors LLC acquired a new stake in shares of Hims & Hers Health in the third quarter worth $672,000. Finally, Wellington Management Group LLP raised its position in Hims & Hers Health by 34.5% in the third quarter. Wellington Management Group LLP now owns 3,444,414 shares of the company’s stock valued at $63,446,000 after purchasing an additional 883,230 shares during the period. Hedge funds and other institutional investors own 63.52% of the company’s stock.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.